Brief: Coya Therapeutics Inc - FDA Unable To Meet Review Goal Date For Coya's Ind For Phase 2 Als Study - SEC Filing
29/07/2025 22:34
Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS INC - FDA UNABLE TO MEET REVIEW GOAL DATE FOR COYA'S IND FOR PHASE 2 ALS STUDY - SEC FILING COYA THERAPEUTICS INC - FDA DECISION ON COYA'S IND EXPECTED BY AUGUST 29, 2025 - SEC FILING Source text: [ID:n0001193125-25-168115] Further company coverage: COYA.O
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)